BRCA2 DNA repair associated

Overview

BRCA2 DNA repair associated (BRCA2) is a tumor suppressor gene located on chromosome 13q12.3 that encodes a large nuclear protein of approximately 3,418 Amino Acids. The protein plays an essential role in maintaining genomic integrity through homologous recombination repair (HRR) — a high-fidelity mechanism by which double-strand DNA breaks are repaired using an undamaged sister chromatid as a template. BRCA2 accomplishes this principally by binding to and stabilizing RAD51 recombinase, facilitating its assembly at sites of DNA damage. Loss-of-function pathogenic variants (PVs) in BRCA2, whether germline or somatic, render cells incapable of accurate HRR, leading to the accumulation of chromosomal aberrations, genomic instability, and loss of heterozygosity — hallmarks of hereditary and sporadic cancers. Alongside its close functional paralog BRCA1, BRCA2 is among the most clinically significant cancer predisposition genes known; germline carriers face substantially elevated lifetime risks for breast, ovarian, pancreatic, and prostate cancers, among others.

The therapeutic relevance of BRCA2 deficiency has grown considerably with the advent of PARP inhibitors, a class of drugs that exploit the concept of synthetic lethality. Because BRCA2-deficient cells cannot perform HRR, they depend disproportionately on base-excision repair mediated by poly(adenosine diphosphate ribose) polymerase (PARP). Pharmacological PARP inhibition in this context leads to irreparable DNA damage and selective tumor cell death. Agents such as olaparib and niraparib have demonstrated efficacy across multiple BRCA2-associated malignancies, fundamentally reshaping the treatment landscape for these cancers.

Focus of Latest Publications

Recent publications have placed BRCA2 at the intersection of genomic medicine, immuno-oncology, and metabolic research, spanning multiple cancer types and clinical contexts.

Lung adenocarcinoma and the tumor microenvironment. A 2026 eLife study (PMID 42189716) examined the molecular architecture of the tumor microenvironment (TME) in human lung adenocarcinoma (LUAD) arising from somatic mutations in BRCA1 and BRCA2. As key regulators of HRR, these genes were found to shape the immunological composition of the TME in ways that remain incompletely understood, motivating multi-omics and single-cell/nuclei analyses to dissect cellular crosstalk between tumor and immune compartments.

breast cancer: surgical outcomes and prognosis. A study published in breast cancer Research and Treatment (PMID 42133182) investigated ipsilateral breast tumor recurrence (IBTR) and prognosis following breast-conserving surgery (BCS) in women carrying BRCA1/2 PVs compared with noncarriers. The work aimed to clarify whether BRCA+ status confers a meaningfully different recurrence risk after BCS, an increasingly common surgical approach even among high-risk patients. Separately, a prospective cohort study in Familial Cancer (PMID 42132994) examined whether the specific gene mutated — BRCA1 versus BRCA2 — differentially affects metabolic phenotypes, finding evidence for impaired glucose tolerance, underscoring that these two genes, though functionally related, may have divergent systemic effects. Another Familial Cancer study (PMID 42126651) surveyed unaffected Israeli BRCA1/BRCA2 PV carriers using a structured questionnaire to understand psychosocial and demographic factors influencing uptake of risk-reducing mastectomy, recognizing that women with PVs in either gene face substantially elevated lifetime breast cancer risk.

Bone metastases and RANKL signaling in hormone receptor-positive breast cancer. A multicenter Italian study in the European Journal of Cancer (PMID 41921366) reported that denosumab — an anti-RANKL monoclonal antibody and anti-osteoporosis drug — was associated with longer real-world progression-free survival in BRCA1/2-mutated hormone receptor-positive (HR+)/HER2-negative breast cancer patients with bone metastases receiving Cdk4/6 inhibitors. This finding was grounded in preclinical evidence suggesting that BRCA1/2-mutated tumors may rely on RANKL signaling for survival and proliferation, opening an unexplored therapeutic intersection between genomic status and bone-targeting agents.

Pancreatic cancer and PARP inhibition. A Phase II trial published in Clinical Cancer Research (PMID 41686836) evaluated niraparib, a PARP inhibitor, in patients with advanced pancreatic cancer harboring PVs in ATM, BRCA1, BRCA2, PALB2, and CHEK2. The rationale drew directly on prior evidence that PARP inhibition is efficacious in platinum-sensitive pancreatic cancer with germline BRCA1/2 PVs, extending the synthetic lethality concept to a broader panel of HRR pathway genes.

ovarian cancer and liquid biopsy alternatives. A case series in Cancer Cytopathology (PMID 42046206) explored the use of malignant ascites as an alternative to tumor tissue for BRCA1/2 next-generation sequencing (NGS) testing in high-grade serous ovarian carcinoma (HGSOC). Given that BRCA1/2 testing is recommended at diagnosis to guide poly(adenosine diphosphate ribose) polymerase inhibitor therapy, validating cytological specimens as a source of diagnostic material has direct clinical utility, particularly for patients in whom solid tissue biopsy is not feasible.

Prostate cancer and immune checkpoint combination. A Phase II study in the Journal for immunotherapy of Cancer (PMID 41881502) investigated olaparib in combination with durvalumab, an checkpoint inhibitor agent targeting PD-L1, in metastatic castration-resistant prostate cancer (mCRPC). Patients with BRCA2 variants experienced markedly longer radiographic progression-free survival (rPFS; 13.2 months) compared with those without BRCA2 variants (4.8 months; p=0.0026), reinforcing the predictive value of BRCA2 status and suggesting potential synergy between PARP inhibition and checkpoint inhibitor in this genomic subgroup.

Hereditary breast cancer heterogeneity and genomic instability. A study in Experimental & Molecular Medicine (PMID 41991965) delineated four disease subtypes underlying genomic instability in hereditary breast cancers using multi-omics data. Homologous recombination-deficient (HRD) tumors exhibited distinct patterns of genomic instability, including promoter hypermethylation and loss of heterozygosity at BRCA1/2, illustrating how epigenetic silencing can phenocopy mutational inactivation of the HRR pathway.

Key Publications

• May Molecular architecture of the tumor microenvironment caused by BRCA1 and BRCA2 somatic mutations in human lung adenocarcinoma. (eLife, 2026, PMID 42189716): "The HRR genes BRCA1/2 are key regulators of DNA repair, yet their impact on the tumor microenvironment (TME) in lung adenocarcinoma (LUAD) remains unclear."
• May Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study. (European journal of cancer (Oxford, England : 1990), 2026, PMID 41921366): "Preclinical evidence suggests that BRCA1/2-mutated tumors may rely on RANKL signaling for survival and proliferation."
• May Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort study. (Familial cancer, 2026, PMID 42132994): "we investigated whether the specific BRCA mutation (BRCA1 vs. BRCA2) has a differential impact on metabolism in women."
• May Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery. (Breast cancer research and treatment, 2026, PMID 42133182): "This study aimed to investigate the differences in the incidence of IBTR and prognosis between BRCA+ and noncarriers (BRCA-) after BCS."
• May Factors influencing uptake of risk-reducing mastectomy among unaffected Israeli BRCA1/BRCA2 pathogenic variant carriers. (Familial cancer, 2026, PMID 42126651): "Women harboring pathogenic variant (PV) in the BRCA1 or BRCA2 genes (= BRCA) have an elevated lifetime risk for breast cancer (BC)."
• May A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026, PMID 41686836): "PARP inhibition has demonstrated efficacy in patients with platinum-sensitive pancreatic cancer with germline BRCA1/2 pathogenic variants (PV)."
• May Exploring alternatives to tumor tissue for BRCA1/2 next-generation sequencing testing in high-grade serous ovarian cancer: A 34-case series of malignant ascites. (Cancer cytopathology, 2026, PMID 42046206): "BRCA1/2 testing is currently recommended at diagnosis for high-grade serous ovarian carcinoma (HGSOC) because of its impact on patients' survival when treated with poly(adenosine diphosphate ribose) polymerase inhibitors."
• Apr Delineation of the heterogeneity underlying genomic instability in hereditary breast cancers reveals four disease subtypes. (Experimental & molecular medicine, 2026, PMID 41991965): "HRD tumors exhibited genomic instability, including promoter hypermethylation and loss of heterozygosity at BRCA1/2."
• Apr Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. (Journal for immunotherapy of cancer, 2026, PMID 41881502): "Patients with BRCA2 variants experienced longer rPFS (13.2 months; 95% CI 7.7 to 20.2 months) than patients without BRCA2 variants (4.8 months; 95% CI 4.5 to 6.4 months, p=0.0026)."